The role of p53 & anaplastic lymphoma kinase genes in the progression of cutaneous CD30+ lymphoproliferative diseases

Indian Journal of Medical Research

Volumn 121, Issue 1, 2005, Pages 46-54

  Kapur, Sujala ^c   Tiemann, Markus ^a   Menke, Martin A O H ^a   Schubert, Christoph ^b   Parwaresch, Reza ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b Safdarjung Hospital ^*  (Germany)

^c SAFDARJUNG HOSPITAL   (India)

Author keywords

Anaplastic kinase gene products; Anaplastic large cell lymphoma; CD30 positive lymphoproliferative diseases; Lyphomatoid papulosis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD30 ANTIGEN; GENE PRODUCT; PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION; STAINING;

ANTIGENS, CD30; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MUTATION; PROTEIN-TYROSINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 14544300204     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 1993; 28: 973-80.
2. Willemze R, Beljaards RC, Meijer CJ. Classification of primary cutaneous T-cell lymphomas. Histopathology 1994; 24: 405-15.
3. Kaudewitz P, Herbst H, Anagnostopoulos I, Eckert F, Braun-Falco O, Stein H. Lymphomatoid papulosis followed by large-cell lymphoma: immunophenotypical and genotypical analysis. Br J Dermatol 1991; 124: 465-9.
4. Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 2001; 14: 219-28.
5. Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653-61.
6. Aoki M, Niimi Y, Takezaki S, Azuma A, Seike M, Kawana S. CD30+ lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma followed by lymphomatoid papulosis. Br J Dermatol 2001; 145: 123-6.
7. Li G, Chooback L, Wolfe JT, Rook AH, Felix CA, Lessin SR, et al. Overexpression of p53 protein in cutaneous T cell lymphoma relationship to large cell transformation and disease progression. J Invest Dermatol 1998; 110: 767-70.
8. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351: 453-6.
9. Benharrouch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ, et al. ALK-positive lymphoma: a singlel disease with a broad spectrum of morphology. Blood 1998; 91: 2076-84.
10. Trinei M, Lanfrancone L, Campo E, Pulford K, Mason DY, Pellicci PG, et al. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res 2000; 60: 793-8.
11. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, Pulford K, Willemze R, Falini B, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol 2000; 53: 445-50.
12. Sambrook J, Fritsch EF, Maniatis T, editors. In: Moleculalr cloning: a laboratory manual. 2nd ed., Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 1989.
13. Herbst H, Sander C, Troinnier M, Kutzner H, Hugel H, Kaudewitz P. Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplstic large cell lymphoma and lymphomatoid papulosis. Br J Dermatol 1997; 137: 680-6.
14. Drexler HG, Gignac SM, von Wasielewski R, Werner M, Dirks WG. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 2000; 14: 1533-59.
15. Cordell JL, Folini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, et al. Immunoenzymatic labeling of monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cylochem 1984; 32: 219-29.
16. Menke MA, Tiemann M, Vogelsang D, Boie C, Parwaresch R. Temperature gradient gel electrophoresis for analysis of a polymerase chain reaction-based diagnostic clonality assay in the early stages of cutaneous T-cell lymphomas. Electrophoresis 1995; 16: 733-8.
17. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acid Res 1996; 24: 141-6.
18. van Haselen CW, Vermeer MH, Toonstra J, van der Putte SC, Mulder PG, van Vloten WA, et al. p53 and bcl-2 expression do not correlate with prognosis in primary cutaneous large T-cell lymphomas. J Cutan Pathol 1997; 24: 462-7.
19. Amagai M, Kawakubo Y, Tsuyuki A, Harada R. Lymphomatoid papulosis followed by Ki-1 positive anaplastic large cell lymphoma: proliferation of a common T-cell clone. J Dermatol 1995; 22: 743-6.
20. Lo CoCo F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82: 2289-95.
21. Cesarman E, Inghirami G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 1993; 143: 845-56.
22. Matinez-Delgado B, Robledo M, Arranz E, Infantes F, Echezarreta G, Marcos B, et al. Correlation between mutations in p53 gene and protein expression in human lymphomas. Am J Hematol 1997; 55: 1-8.
23. Turturro F, Frist AY, Arnold MD, Pal A, Cook GA, Seth P. Comparison of the effects of recombinant adenovirus-mediated expression of wild-type p53 and p27Kip 1 on cell cycle and apoptosis in SUDHL-1 cells derived from anaplastic large cell lymphoma. Leukemia 2001; 15: 1225-31.
24. Vergier B, Beylot-Barry M, Pulford K, Michel P, Bosq J, de Muret A, et al. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol 1998; 22 1192-1202.